Navigation Links
Pipeline for Breast Cancer Therapies is Focus of New MedPredict Report
Date:8/27/2008

SCOTTSDALE, Ariz., Aug. 27 /PRNewswire/ -- MedPredict has published a new report in its oncology series entitled "Thought Leader Insight & Analysis: Breast Cancer," designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for diagnostics and treatments in this disease area. MedPredict interviewed renowned North American and European breast cancer thought leaders to identify the most promising candidates in clinical development, as well as explore unmet needs. They address the following questions:

-- Has Novartis jumped ahead of Amgen in developing a breast cancer drug that provides a mortality benefit and preserves bone? MedPredict's panel debates the implications of Novartis' positive zoledronic acid (Zometa) data presented at ASCO 2008.

-- How prevalent is osteonecrosis of the jaw with antiresorptives, and how will this affect their usage in breast cancer?

-- How is triple negative breast cancer being treated, and where are the opportunities for development in this subtype?

-- What are the best approaches for development of inhibitors of mTOR, IGF1R, EGFR, PARP-1, HSP90, Src, angiogenesis, FA2, hedgehog, and vaccines?

"This report will provide essential strategic insight for those involved in development of breast cancer therapies," according to MedPredict President Dr. Jeffrey Berk. "Our report discusses ongoing clinical programs, and offers insight into which of the many new drugs in development are likely to be significant improvements over current options."

Companies included in this report: Abbott (ABT-888, ABT-999, A-928605), Abraxis/AstraZeneca (Abraxane), Amgen (denosumab, AMG-479), AstraZeneca (Arimidex, olaparib, saracatinib), Bayer-Schering (Bonefos), BiPar (BSI-201, BSI-401), Boehringer Ingelheim (Tovok), Bristol-Myers Squibb (brivanib, BMS-754807, Sprycel, Ixempra), BMS/Imclone (Erbitux), Exelixis (XL-765, XL-647), Genentech (Avastin, GDC-0941, Herceptin, pertuzumab, trastuzumab-DM1), GlaxoSmithKline (Tykerb), Imclone (IMC-A12, IMC-1121B), Kosan (tanespimycin), Merck (Fosamax, odanacatib, MK-0646), Myriad (BRCA1/BRCA2 Screening), Merck/Ariad (deforolimus), Novartis (Zometa, Femara, everolimus, patupilone, TAE-266), OSI (OSI-906), Pfizer (Aromasin, Sutent, Tarceva, CP-751871), Pierre Fabre (Javlor), Roche/GSK (Boniva), Roche (Xeloda), Sanofi-Aventis (AVE-1642), Schering-Plough (SCH-717454), and Wyeth (Torisel, neratinib).

The full report can be purchased by contacting MedPredict.

About MedPredict

MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders. Based on primary interviews with these thought leaders, MedPredict publishes periodic therapeutic area reports to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and presentations, as well as clinical, regulatory and marketing activity.


'/>"/>
SOURCE MedPredict
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. The Michigan Life Sciences Pipeline Adds More Resources On Its Website
2. Alexza to Announce 2008 Second Quarter Financial Results and Update Its Clinical Pipeline on Wednesday, August 6, 2008
3. SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update
4. BioMS Medical Provides Update On Pipeline Products
5. SGX Pharmaceuticals Schedules Teleconference and Webcast to Discuss First Quarter 2008 Results and Provide Pipeline Update
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
7. Abbott Annual Meeting Highlights Outstanding 2007 Results, International Growth and Near-Term Pipeline
8. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
9. Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
10. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
11. Pipeline for Lung Cancer Therapies is Focus of New MedPredict Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Mass. , March 23, 2017 /PRNewswire/ ... partner to global in vitro diagnostics manufacturers ... of the industry,s first multiplexed Inherited ... disease testing by next-generation sequencing (NGS). The ... were developed with input from industry experts ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... was recently selected by the Connecticut Technology Council (CTC) as a 2017 Women ... CTC’s thirteenth annual Women of Innovation Awards Dinner. , The dinner recognizes women ...
(Date:3/23/2017)... , March 23, 2017 According to ... products and derivatives market is fragmented due to the presence of a ... as Proliant, Thermo Fisher , and Sigma-Aldrich, compete with each ... three companies, collectively, held more than 76% of this market in ... As of ...
(Date:3/23/2017)... ... March 23, 2017 , ... Advanced Polymer Monitoring Technologies (APMT), ... Sigmund “Sig” Floyd as Vice President ? Global Business Development. Dr. Floyd will ... “Dr. Floyd’s career has spanned 30 years in the chemicals and equipment industries. ...
Breaking Biology Technology:
(Date:2/28/2017)... , Spanien, 27. Februar 2017  EyeLock LLC, ein ... wird seine erstklassige biometrische Lösung zur Iris-Erkennung ... mit X16 LTE auf dem Mobile World ... am Qualcomm-Stand in Halle 3, Stand 3E10, ... die Sicherheitsplattform Qualcomm Haven™ – eine Kombination ...
(Date:2/24/2017)... , Feb. 24, 2017  EyeLock LLC, a leader ... its elite iris biometric solution on the latest ... LTE at Mobile World Congress 2017 (February ... Booth in Hall 3, Stand 3E10. ... Qualcomm Haven™ security platform—a combination of hardware, ...
(Date:2/21/2017)... -- Der weltweite Biobanking-Sektor wird bis zum ... mit mehr als 50 Vertretern aus verschiedenen Branchen wurde aber ... diese Prognose zu realisieren. ... Zu den Schwierigkeiten für ... für die Biobank, die Implementierung Zeit sparender Technologien, ein ...
Breaking Biology News(10 mins):